期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 415, 期 2-3, 页码 117-125出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/S0014-2999(01)00834-2
关键词
MAP kinase; phosphatidylcholine-specific phospholipase C; imidazoline I-1 receptor; PC12 cell; diacylglycerol; rilmenidine
资金
- NIAAA NIH HHS [R01 AA007839, AA07839] Funding Source: Medline
In the present study, we tested the hypothesis that the activation of imidazoline I-1-receptor, which is coupled to phosphatidylcholine-specific phospholipase C, results in downstream activation of mitogen-activated protein kinase (p42(mapk) and p44(mapk) isoforms) in PC12 cells. PC12 cells pretreated with nerve growth factor (50 ng/ml, 48 h) to initiate neuronal differentiation were incubated with [methyl-H-3]choline and [H-3]myristate. Activation of imidazoline I, receptor by rilmenidine (10 muM) caused time-dependent increases in diacylglycerol accumulation and phosphocholine release. The Western blotting analysis showed that rilmenidine (10 muM) produced a time-dependent activation of p42(mapk) and p44(mapk) that reached its maximum at 15 min and returned to control levels after 30 min. This finding was confirmed by immunofluorescence labeling of activated mitogen-activated protein kinase in the same model system. Efaroxan (imidazoline I1-receptor antagonist) or tricyclodecan-9-yl-xanthogenate (D609, phosphatidylcholine-specific phospholipase C inhibitor) attenuated the phosphorylation of p42(mapk) and p44(mapk) induced by rilmenidine. Nerve growth factor-induced phosphorylation of both mitogen-activated protein kinase isoforms was not affected by D609. These results support the hypothesis that the activation of the imidazoline I, receptor coupled phosphatidylcholine-specific phospholipase C results in the downstream activation of mitogen-activated protein kinase. (C) 2001 Elsevier Science B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据